Pioneering diagnostics
E.g., 29/03/2020
E.g., 29/03/2020
PreviousNext

First-Half 2018 Results

05 September, 2018

  • Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
    • €1,169 million in sales
    • Up 3.1% as reported
  • Contributive operating income before non-...

Second-Quarter 2018 Business Review

18 July, 2018

  • Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
    • €1,169 million in sales 
    • Up 3.1% as reported
  • ...

NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysis Quality Initiative Recommendations

12 June, 2018

The biomarkers in the NEPHROCHECK® test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute kidney injury (...

bioMérieux launches ENDOZYME® II GO, an innovative test for the detection of endotoxins in pharmaceutical microbiology control

31 May, 2018

bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe crab Factor C (rFC) assays. This new...

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking Consensus Statement of Best Practices to Enhance Recovery after Heart Surgery

02 May, 2018

Marcy l’Étoile (France) and San Diego (California) - May 2nd, 2018 – The biomarkers in the...

bioMérieux and the University of Antwerp award scholarships to three healthcare professionals for their commitment to improve antibiotic use in order to combat antimicrobial resistance  

23 April, 2018

Marcy l'Étoile (France) – Antwerp (Belgium) – April 23, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, and the Laboratory of Medical Microbiology at the University of Antwerp have awarded three scientific scholarships within the scope of the Global...

bioMérieux – First-Quarter 2018 Business Review

19 April, 2018

  • Strong sales dynamic in first-quarter 2018, with sales up 12.5% at constant exchange rates and scope of consolidation:
    • €587 million in sales 
    • Up 3.4% as reported
  • Growth driven by molecular biology in...

bioMérieux submits for FDA Clearance of the  BIOFIRE® FILMARRAY® Pneumonia Panel  

19 April, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel....

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

04 April, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation...

2017 Financial Results

28 February, 2018

  • Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation:
    • €2,288 million in sales
    • Up 8.8% as reported
  • Strong 12.4% increase in contributive operating income before non-recurring items...

PreviousNext